Publications by authors named "M Ramello"
Tumor-infiltrating lymphocyte (TIL) hypofunction contributes to the progression of advanced cancers and is a frequent target of immunotherapy. Emerging evidence indicates that metabolic insufficiency drives T cell hypofunction during tonic stimulation, but the signals that initiate metabolic reprogramming in this context are largely unknown. Here, we found that Meteorin-like (METRNL), a metabolically active cytokine secreted by immune cells in the tumor microenvironment (TME), induced bioenergetic failure of CD8 T cells.
View Article and Find Full Text PDFTo investigate the impact of natremia in metastatic colorectal cancer (mCRC) patients treated with aflibercept plus folinic acid, 5-fluorouracil, oxaliplatin and irinotecan (FOLFIRI). A total of 84 mCRC patients receiving aflibercept plus FOLFIRI as second-line treatment were enrolled and divided into two groups based on their median sodium value. Progression-free survival and overall survival were analyzed.
View Article and Find Full Text PDFArticle Synopsis
- Conventional CD4 T lymphocytes, particularly those expressing CD39, play a critical, yet not fully understood, role in fighting tumors, showing distinct characteristics in cancer environments.
- In mouse cancer models, these CD39 Tconv cells displayed traits of exhaustion, high cytotoxic potential, and specific protein expressions, differentiating them from their counterparts in lymphoid organs.
- In breast cancer patients, CD39 Tconv cells were less common in non-tumoral tissues and linked to improved survival rates, highlighting CD39 as a potential biomarker for assessing immune responses in tumors.
Pancreatic cancer (PC) is one of the most lethal malignancies worldwide. This study evaluated the prognostic role of serum alanine phosphatase (ALP) and gamma-glutamyl-transferase (GGT) in metastatic PC patients. 153 patients with metastatic PC receiving first-line treatment with nab-paclitaxel/gemcitabine were retrospectively enrolled in a multicenter study and stratified according to ALP (≤ or >260 U/l) and GGT (≤ or >45.
View Article and Find Full Text PDFThe phase III MPACT trial demonstrated the superiority of gemcitabine plus nab-paclitaxel (NABGEM) versus gemcitabine alone in previously untreated patients with metastatic pancreatic cancer (mPC). The aim of this study was to evaluate the responses in terms of efficacy and safety in patients treated with more than 6 cycles of chemotherapy. From January 2015 to December 2018, patients with mPC receiving first-line treatment with NABGEM were included in a multicentre retrospective observational study.
View Article and Find Full Text PDF